The stereoselective metabolism of halofantrine to desbutylhalofantrine in the rat: Evidence of tissue-specific enantioselectivity in microsomal metabolism

Chirality

Volumn 19, Issue 1, 2007, Pages 22-33

  Gharavi, Negar ^a   Sattari, Somayeh ^a   Shayeganpour, Anooshirvan ^a   El Kadi, Ayman O S ^a   Brocks, Dion R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antimalarial; Cytochrome P450; Inhibition; Metabolism; Microsomal; Pharmacokinetics

Indexed keywords

ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2C11; CYTOCHROME P450 2D1; CYTOCHROME P450 3A1; DEBUTYLHALOFANTRINE; DRUG METABOLITE; HALOFANTRINE; KETOCONAZOLE; RECOMBINANT ENZYME;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENANTIOSELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; INTESTINE; LIVER MICROSOME; MALARIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY; TISSUE SPECIFICITY;

EID: 33845565132     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20334     Document Type: Article

References (39)

1. Basco LK, Gillotin C, Gimenez F, Farinotti R, Le Bras J. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol 1992;33:517-520.
2. Karle JM, Olmeda R, Gerena L, Milhous WK. Plasmodium falciparum: Role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. Exp Parasitol 1993;76: 845-351.
3. Gimenez F, Aubry AF, Farinotti R, Kirkland K, Wainer IW. The determination of the enantiomers of halofantrine and monodesbutyl-halofantrine in plasma and whole blood using sequential achiral/chiral high-performance liquid chromatography. J Pharm Biomed Anal 1992;10:245-250.
4. Brocks DR, Dennis MJ, Schaefer WH. A liquid chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. J Pharm Biomed Anal 1995;13:911-918.
5. Gimenez F, Gillotin C, Basco LK, Bouchaud O, Aubry AF, Wainer IW, Le Bras J, Farinotti R. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol 1994;46:561-562.
6. Wesche DL, Schuster BG, Wang WX, Woosley RL. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 2000;67:521-529.
7. Monlun E, Le Metayer P, Szwandt S, Neau D, Longy-Boursier M, Horton J, Le Bras M. Cardiac complications of halofantrine: A prospective study of 20 patients. Trans R Soc Trop Med Hyg 1995;89:430-433.
8. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993;341:1054-1056.
9. Brocks DR, Mehvar R. Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. Clin Pharmacokinet 2003;42:1359-1382.
10. Brocks DR. Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. Biopharm Drug Dispos 2000;21: 365-371.
11. Brocks DR, Toni JW. Pharmacokinetics of halofantrine in the rat: Stereoselectivity and interspecies comparisons. Biopharm Drug Dispos 1999;20:165-169.
12. Bryson HM, Goa KL. Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992;43: 236-258.
13. Karbwang J, Na Bangchang K. Clinical phannacokinetics of halofantrine. Clin Pharmacokinet 1994;27:104-119.
14. Brocks DR. Stereoselective halofantrine and desbutylhalofantrine disposition in the rat: Cardiac and plasma concentrations and plasma protein binding. Biopharm Drug Dispos 2002;23:9-15.
15. Brocks DR, Wasan KM. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. J Pharm Sci 2002;91:1817-1826.
16. Milton KA, Edwards G, Ward SA, Orme ML, Breckenridge AM. Pharmacokinetics of halofantrine in man: Effects of food and dose size. Br J Clin Pharmacol 1989;28:71-77.
17. Trevaskis NL, Porter CJ, Charman WN. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. Drug Metab Dispos 2006;34:729-733.
18. Terefe H, Blaschke G. Direct determination of the enantiomers of halofantrine and its pharmacologically active metabolite N-desbutyl-halofantrine by high-performance liquid chromatography. J Chromatogr 1993;615:347-351.
19. Baune B, Flinois JP, Furlan V, Gimenez F, Taburet AM, Becquemont L, Farinotti R. Halofantrine metabolism in microsomes in man: Major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol 1999;51:419-426.
20. Halliday RC, Jones BC, Smith DA, Kitteringham NR, Park BK. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 1995;40:369-378.
21. Baune B, Furlan V, Taburet AM, Farinotti R. Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes. Drug Metab Dispos 1999;27:565-568.
22. Khoo SM, Porter JH, Edwards GA, Charman WN. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. J Pharm Sci 1998;87:1538-1541.
23. Lowry OH, Rosebrough NJ, Farr AL, Handall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
24. Matthew D, Brennan B, Zomorodi K, Houston JB. Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver. Pharm Res 1993;10:418-422.
25. Brocks DR. A high-performance liquid chromatographic assay for the determination of desbutylhalofantrine enantiomers in rat plasma. J Pharm Pharm Sci 2001;4:24-31.
26. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004;32:447-454.
27. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions: Application and clinical value of in vitro models. Curr Drug Metab 2003;4:423-459.
28. Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953;55:170-171.
29. Cortes A, Cascante M, Cardenas ML, Cornish-Bowden A. Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: New ways of analysing data. Biochem J 2001;357:263-268.
30. Krishna S, ter Kuile K, Supanaranond W, Pukrittayakamee S, Teja-Isavadharm P, Kyle D, White NJ. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br J Clin Pharmacol 1993;36:585-591.
31. Lindell M, Lang M, Lennernas H. Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver. Eur J Drug Metab Pharmacokinet 2003;28:41-48.
32. Matsubara T, Kim HJ, Miyata M, Shimada M, Nagata K, Yamazoe Y. Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther 2004;309:1282-1290.
33. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez EJ, Gelboin HV, Shou M. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 2000;30:327-343.
34. Turan VK, Mishin VM, Thomas PE. Clotrimazole is a selective and potent inhibitor of rat cytochrome P450 3A subfamily-related testosterone metabolism. Drug Metab Dispos 2001;29:837-842.
35. Eagling VA, Tjia JE, Back DJ. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998;45:107-114.
36. Paine MF, Schmiedlin-Ren P, Watkins PB. Cytochrome P-450 1A1 expression in human small bowel: Interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 1999;27:360-364.
37. Shayeganpour A, El-Kadi AO, Brocks DR. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: The contribution of cytochrome P450 3A isoforms. Drug Metab Dispos 2006;34:43-50.
38. Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, McSurdy-Freed JE, Proksch JW, Smith BR. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 2004;32:172-177.
39. Reed MB, Saliba KJ, Caruana SK, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000;403:906-999.